Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

ZBIO

+ Watchlist+ Portfolio

Zenas BioPharma, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$27.75
52-Week Range
$13.50 – $44.60
Market Cap
$1.79B
P/E (TTM)
—
EPS (TTM)
-10.08
Dividend Yield
0.00%
Advanced Metrics
Price/Book
8.44
PEG Ratio
—
Return on Equity
-265.11%
Return on Assets
-36.77%
Gross Margin
0.00%
Operating Margin
-2666.64%
Profit Margin
0.00%
Current Ratio
9.42
Debt/Equity
1.42
Total Debt
$300.89M
Free Cash Flow
$-250.62M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.51B

Market Snapshot

About

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies for autoimmune and inflammatory diseases. The company leverages its expertise in T-cell biology to develop novel treatments targeting unmet medical needs. Zenas BioPharma aims to bring innovative therapies to patients with serious immune-mediated conditions.